BPC-157 + TB-500
5 mg + 5 mg
$69.00
BPC-157 is a synthetic pentadecapeptide derived from a gastric protective protein sequence, supplied as a lyophilized (freeze-dried) powder vial paired with a separate vial of bacteriostatic water for reconstitution. Mix on-site just before first use.
For research and clinical use only. Supplied to licensed practitioners and research professionals. Not evaluated by the FDA.
BPC-157 is a synthetic pentadecapeptide derived from a gastric protective protein sequence, supplied as a lyophilized (freeze-dried) powder vial paired with a separate vial of bacteriostatic water for reconstitution. Mix on-site just before first use.
Supplied to licensed practitioners and research professionals only. Reconstitute under aseptic conditions with bacteriostatic water. Store lyophilized at −20 °C protected from light; keep reconstituted material at 2–8 °C and avoid repeated freeze-thaw cycles. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
| Available sizes | 5 mg — $29.00 · 10 mg — $49.00 |
| Form | Lyophilized powder + BAC water vial |
| Molecular weight | 1419.5 g/mol |
| CAS | 137525-51-0 |
| Sequence length | 15 |
| Storage — sealed | −20 °C, protected from light |
| Storage — reconstituted | 2–8 °C, use within 14 days |
| Ships from | Chicago, IL |
| SKU | PEP-BPC |
Research summary — for laboratory and research use only. Not medical advice, not a dosing recommendation, and not an FDA evaluation of safety or efficacy.
First characterized in the 1990s at the University of Zagreb by Predrag Sikirić's group, BPC-157 ("Body Protection Compound") is a partial, stable sequence derived from human gastric juice. It is not a natural, isolated hormone but a synthetic peptide built to mimic the protective fragment identified in that early work.
The proposed mechanism centers on modulation of the nitric oxide (NO) system and upregulation of VEGFR2-mediated angiogenesis. In rodent models, BPC-157 has been reported to promote fibroblast migration and formation of new blood vessels at injury sites, and to influence the growth-hormone receptor pathway involved in tendon and ligament repair. These findings come from preclinical animal studies; the compound has not gone through the human clinical-trial process the FDA requires for a marketed drug.
The original research line examined protective effects on gastric and intestinal mucosa in rodent ulcer and fistula models, which is where the compound's name originates.
A body of rodent surgical literature has looked at BPC-157's effect on tendon, ligament and bone-healing timelines, often in the context of Achilles or quadriceps tendon transection models.
Multiple groups have studied its interaction with the NO-synthase pathway and VEGFR2 signalling as a proposed driver of the angiogenic effects reported in injury models.
Supplied to licensed practitioners and research professionals only. Reconstitute under aseptic conditions with bacteriostatic water. Store lyophilized at −20 °C protected from light; keep reconstituted material at 2–8 °C and avoid repeated freeze-thaw cycles. Not evaluated by the FDA and not intended to diagnose, treat, cure or prevent any disease.
No. BPC-157 is not an FDA-approved drug, is not a dietary supplement, and the FDA has specifically flagged it as a bulk substance with safety concerns for compounding. It is supplied here strictly for laboratory and research use.
As a lyophilized powder reconstituted with bacteriostatic water immediately before use, stored frozen when sealed and refrigerated once reconstituted — see the Handling tab for full detail.
Further reading: for the published preclinical and clinical literature on BPC-157, search PubMed. We link to the search rather than cherry-picked citations so you can review the current, full body of literature yourself.